Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Aaron Wealth Advisors LLC

Aaron Wealth Advisors LLC increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 6.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 21,572 shares of the company’s stock after buying an additional 1,396 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,856,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Strategic Investment Solutions Inc. IL acquired a new position in shares of Novo Nordisk A/S during the 2nd quarter worth approximately $25,000. Daiwa Securities Group Inc. purchased a new stake in Novo Nordisk A/S in the 3rd quarter worth $28,000. Capital Performance Advisors LLP acquired a new position in Novo Nordisk A/S during the third quarter worth $42,000. Carolina Wealth Advisors LLC purchased a new position in Novo Nordisk A/S during the third quarter valued at $48,000. Finally, M&R Capital Management Inc. grew its position in shares of Novo Nordisk A/S by 260.5% in the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after purchasing an additional 297 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $78.74 on Friday. The business’s 50 day moving average price is $97.76 and its 200 day moving average price is $117.23. The company has a market cap of $353.33 billion, a price-to-earnings ratio of 25.48, a PEG ratio of 0.92 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.